Factors Associated With Immune Checkpoint Inhibitor–Related Myocarditis

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · see citing works

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Salem, J.-E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., Gobert, A., Spano, J.-P., Balko, J. M., Bonaca, M. P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30608-9 · Cited by 1,271 · see citing works

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw443 · Cited by 817 · see citing works

Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non–Small-cell Lung Cancer

Owen, D. H., Wei, L., Bertino, E. M., Edd, T., Villalona-Calero, M. A., He, K., Shields, P. G., Carbone, D. P., & Otterson, G. A. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.08.008 · Cited by 145 · see citing works

The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood

Kytö, V., Sipilä, J., & Rautava, P. (2013) · Heart · doi:10.1136/heartjnl-2013-304449 · Cited by 124 · see citing works

Sex differences in tolerability to Anti-PD1 therapy: Are we all equal?

Duma, N., Paludo, J., Enninga, E. A. L., Yadav, S., Vera-Aguilera, J., Kottschade, L. A., Dong, H., Adjei, A. A., & Dronca, R. S. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9547 · Cited by 2 · see citing works

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Lyon, A. R., López‐Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J. K., Boriani, G., Cardinale, D. M., Córdoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,301 · see citing works

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Lyon, A. R., López‐Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J. K., Boriani, G., Cardinale, D. M., Córdoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 531 · see citing works

Endocrine toxicities of immune checkpoint inhibitors

Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441 · see citing works

T cells specific for α-myosin drive immunotherapy-related myocarditis

Axelrod, M. L., Meijers, W. C., Screever, E. M., Qin, J., Carroll, M. G., Sun, X., Tannous, E., Zhang, Y., Sugiura, A., Taylor, B. C., et al. (2022) · Nature · doi:10.1038/s41586-022-05432-3 · Cited by 367 · see citing works

A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention

Wei, S. C., Meijers, W. C., Axelrod, M. L., Anang, N.-A. A. S., Screever, E. M., Wescott, E. C., Johnson, D. B., Whitley, E., Lehmann, L., Courand, P.-Y., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0856 · Cited by 290 · see citing works

Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy

Gil-Cruz, C., Perez-Shibayama, C., De Martin, A., Ronchi, F., van der Borght, K., Niederer, R., Onder, L., Lütge, M., Novkovic, M., Nindl, V., et al. (2019) · Science · doi:10.1126/science.aav3487 · Cited by 260 · see citing works

Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis

Zhu, H., Galdos, F. X., Lee, D., Waliany, S., Huang, Y. V., Ryan, J., Dang, K., Neal, J. W., Wakelee, H. A., Reddy, S. A., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.056730 · Cited by 192 · see citing works

The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity

Zhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N. L., & Neilan, T. G. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.11.012 · Cited by 145 · see citing works

Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis

Won, T., Kalinoski, H. M., Wood, M. K., Hughes, D. M., Jaime, C. M., Delgado, P., Talor, M. V., Lasrado, N., Reddy, J., & Čiháková, D. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111611 · Cited by 137 · see citing works

Immune Checkpoint Inhibitor–Induced Cardiotoxicity

Nielsen, D. L., Juhl, C. B., Nielsen, O. H., Chen, I. M., & Herrmann, J. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.3065 · Cited by 128 · see citing works

Harnessing big data to characterize immune-related adverse events

Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00597-8 · Cited by 125 · see citing works

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy

Jing, Y., Chen, X., Li, K., Liu, Y., Zhang, Z., Chen, Y., Liu, Y., Wang, Y., Lin, S. H., Diao, L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003779 · Cited by 117 · see citing works

Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy

Jing, Y., Zhang, Y., Wang, J., Li, K., Chen, X., Heng, J., Gao, Q., Ye, Y., Zhang, Z., Liu, Y., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab035 · Cited by 102 · see citing works

Atherosclerosis With Immune Checkpoint Inhibitor Therapy

Abreu, G. A. S., Zanni, M. V., & Neilan, T. G. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.11.011 · Cited by 103 · see citing works

Sex-Specific Cardiovascular Risks of Cancer and Its Therapies

Wilcox, N. S., Rotz, S. J., Mullen, M., Song, E. J., Ky Hamilton, B., Moslehi, J., Armenian, S. H., Wu, J. C., Rhee, J.-W., & Ky, B. (2022) · Circulation Research · doi:10.1161/circresaha.121.319901 · Cited by 86 · see citing works

Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure

Waliany, S., Lee, D. C., Witteles, R. M., Neal, J. W., Nguyen, P. K. P., Davis, M. M., Salem, J., Wu, S. M., Moslehi, J. J., & Zhu, H. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023451 · Cited by 75 · see citing works

Toxicity in the era of immune checkpoint inhibitor therapy

Keam, S., Turner, N., Kugeratski, F. G., Rico, R., Colunga-Minutti, J., Poojary, R., Alekseev, S., Patel, A. B., Li, Y. J., Sheshadri, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1447021 · Cited by 76 · see citing works

Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study

Okada, N., Matsuoka, R., Sakurada, T., Goda, M., Chuma, M., Yagi, K., Zamami, Y., Nishioka, Y., & Ishizawa, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-70743-2 · Cited by 69 · see citing works

Equity in Cardio-Oncology Care and Research: A Scientific Statement From the American Heart Association

Addison, D., Branch, M. E., Baik, A. H., Fradley, M. G., Okwuosa, T. M., Reding, K. W., Simpson, K. E., Abreu, G. A. S., Yang, E. H., & Yancy, C. W. (2023) · Circulation · doi:10.1161/cir.0000000000001158 · Cited by 68 · see citing works

Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis

Zhang, Y., Sun, C., Li, Y., Qin, J., Amancherla, K. V., Jing, Y., Hu, Q., Liang, K., Zhang, Z., Ye, Y., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo1981 · Cited by 66 · see citing works

Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy

Shah, K. P., Song, H., Ye, F., Moslehi, J. J., Balko, J. M., Salem, J.-E., & Johnson, D. B. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0986 · Cited by 64 · see citing works

Myocarditis: Etiology, Pathogenesis, and Their Implications in Clinical Practice

Brociek, E., Tymińska, A., Giordani, A. S., Caforio, A. L. P., Wojnicz, R., Grabowski, M., & Ozierański, K. (2023) · Biology · doi:10.3390/biology12060874 · Cited by 69 · see citing works

Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data

Makunts, T., Saunders, I. M., Cohen, I. V., Li, M., Moumedjian, T., Issa, M. A., Burkhart, K., Lee, P., Patel, S. P., & Abagyan, R. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-96467-5 · Cited by 54 · see citing works

Cardiovascular toxicity of immune therapies for cancer

Palaskas, N. L., Ali, H.-J., Koutroumpakis, E., Ganatra, S., & Deswal, A. M. (2024) · BMJ · doi:10.1136/bmj-2023-075859 · Cited by 53 · see citing works

Autoimmune Myocarditis, Old Dogs and New Tricks.

Won, T., Song, E. J., Kalinoski, H. M., Moslehi, J. J., & Čiháková, D. (2024) · Circulation Research · doi:10.1161/circresaha.124.323816 · Cited by 51 · see citing works

Immunotherapy to treat malignancy in patients with pre-existing autoimmunity

Boland, P., Pavlick, A. C., Weber, J., & Sandigursky, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000356 · Cited by 50 · see citing works

Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects

Herrmann, J., Barac, A., Carver, J. R., Cheng, R. K.-H., Daniele, A. J., Dent, S. F., Deych, E., Lee, D. H., Lenihan, D. J., Leong, D. P., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.4543 · Cited by 51 · see citing works

Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities

Yousif, L. I., Screever, E. M., Versluis, D., Aboumsallem, J. P., Nierkens, S., Manintveld, O. C., de Boer, R. A., & Meijers, W. C. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01414-4 · Cited by 51 · see citing works

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians

Raschi, E., Rossi, S., Giglio, A. D., Fusaroli, M., Burgazzi, F., Rinaldi, R., & Potena, L. (2023) · Drug Safety · doi:10.1007/s40264-023-01320-5 · Cited by 47 · see citing works

Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database

Hasegawa, S., Ikesue, H., Nakao, S., Shimada, K., Mukai, R., Tanaka, M., Matsumoto, K., Inoue, M., Satake, R., Yoshida, Y., et al. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5108 · Cited by 44 · see citing works

Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors

Baik, A. H., Tsai, K. K., Oh, D. Y., & Aras, M. A. (2021) · Clinical Science · doi:10.1042/cs20200331 · Cited by 42 · see citing works

Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities

Goodman, R. S., Jung, S., Balko, J. M., & Johnson, D. B. (2023) · Immunological Reviews · doi:10.1111/imr.13249 · Cited by 36 · see citing works

Immune checkpoint inhibitors in metastatic melanoma therapy (Review)

Shah, V., Panchal, V. S., Shah, A., Vyas, B., Agrawal, S. P., & Bharadwaj, S. P. (2024) · Medicine International · doi:10.3892/mi.2024.137 · Cited by 36 · see citing works

Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study

Noseda, R., Ruinelli, L., van der Gaag, L. C., & Ceschi, A. (2020) · Cancers · doi:10.3390/cancers12113480 · Cited by 31 · see citing works

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do

Zito, C., Manganaro, R., Ciappina, G., Spagnolo, C. C., Racanelli, V., Santarpía, M., Silvestris, N., & Carerj, S. (2022) · Cancers · doi:10.3390/cancers14215403 · Cited by 31 · see citing works

Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses

Canzian, J., Conforti, F., Jacobs, F., Benvenuti, C., Gaudio, M., Gerosa, R., Sanctis, R. D., & Zambelli, A. (2025) · Cancers · doi:10.3390/cancers17071054 · Cited by 31 · see citing works

Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies

Ronen, D., Bsoul, A., Lotem, M., Abedat, S., Yarkoni, M., Amir, O., & Asleh, R. (2022) · Vaccines · doi:10.3390/vaccines10040540 · Cited by 28 · see citing works

Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy

Cone, E. B., Haeuser, L., Reese, S. W., Marchese, M., Nguyen, D., Nabi, J., Chou, W. H., Noldus, J., McKay, R. R., Kilbridge, K. L., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272022 · Cited by 28 · see citing works

Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy

Buehning, F., Lerchner, T., Vogel, J., Hendgen-Cotta, U. B., Totzeck, M., Rassaf, T., & Michel, L. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01070-0 · Cited by 27 · see citing works

Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors

Isawa, T., Toi, Y., Sugawara, S., Taguri, M., & Toyoda, S. (2022) · The Oncologist · doi:10.1093/oncolo/oyac056 · Cited by 27 · see citing works

Autoimmunity in immune checkpoint inhibitor‐induced immune‐related adverse events: A focus on autoimmune skin toxicity and pneumonitis

Berner, F., & Flatz, L. (2023) · Immunological Reviews · doi:10.1111/imr.13258 · Cited by 28 · see citing works

Advances in immune checkpoint inhibitors induced-cardiotoxicity

Li, X., Peng, W., Wu, J., Yeung, S. J., & Yang, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130438 · Cited by 27 · see citing works

A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers

Xu, L., Chen, Y., Xiong, L., Shen, Y., Zhou, Z., Wang, S., & Xu, X. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2512645 · Cited by 26 · see citing works

Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy

Cheng, E., Ivanovic, M., Chan, A., Xu, S., Franquiz, M. J., Lee, C., You, J., Fazal, M., Guen, Y. L., Batchelder, R., et al. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.06.009 · Cited by 25 · see citing works

Central memory CD4+ T cells play a protective role against immune checkpoint inhibitor–associated myocarditis

Yu, J., Long, B., Li, Z., Tian, X., Li, D., Long, J., Wang, Y., Chen, Y., Zhang, F., Liu, H., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae133 · Cited by 22 · see citing works

Immune checkpoint inhibitor-associated myocarditis: a historical and comprehensive review

Jensen, G. L., Wang, X., Kuempel, J., Palaskas, N. L., Chen, Z., Yu, W., Chen, Y., Mohammad, H., Luo, W., & Chang, J. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00687.2024 · Cited by 23 · see citing works

Anti‐CTLA‐4 m2a Antibody Exacerbates Cardiac Injury in Experimental Autoimmune Myocarditis Mice By Promoting Ccl5‐Neutrophil Infiltration

Wu, M., Yang, Y., Cai, Y., Jiang, S., Xiao, H., Miao, C., Jin, X., Sun, Y., Bi, X., Hong, Z., et al. (2024) · Advanced Science · doi:10.1002/advs.202400486 · Cited by 21 · see citing works

Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report

Cham, J., Ng, D. K.-K., & Nicholson, L. J. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-02858-7 · Cited by 22 · see citing works

Immune checkpoint inhibitor-associated cardiovascular toxicities: A review

Liu, G., Chen, T., Zhang, X., Hu, B., & Shi, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25747 · Cited by 22 · see citing works

Concomitant Proton Pump Inhibitors and Immune Checkpoint Inhibitors Increase Nephritis Frequency

Kato, K., Mizuno, T., Koseki, T., Ito, Y., Hatano, M., Takahashi, K., Yamada, S., & Tsuboi, N. (2021) · In Vivo · doi:10.21873/invivo.12570 · Cited by 20 · see citing works

Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study

Basak, E. A., Vermeer, N. S., de Joode, K., Hurkmans, D. P., Velthuis, D. E. M., Hoop, E. O., Schreurs, M. W. J., Bins, S., Koolen, S. L. W., Debets, R., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.07.015 · Cited by 20 · see citing works

Atrial Fibrillation and Cancer—Epidemiology, Mechanisms, and Management

Davis, N. E., Prasitlumkum, N., & Tan, N. Y. L. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247753 · Cited by 19 · see citing works

Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research

Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J. W., Witteles, R. M., Nguyen, P. K. P., Cheng, P. P., & Zhu, H. (2023) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-023-01024-0 · Cited by 19 · see citing works

Real-World Prevalence and Tolerability of Immune-Related Adverse Events in Older Adults with Non-Small Cell Lung Cancer: A Multi-Institutional Retrospective Study

Matsukane, R., Oyama, T., Tatsuta, R., Kimura, S., Hata, K., Urata, S., & Watanabe, H. A. (2024) · Cancers · doi:10.3390/cancers16112159 · Cited by 19 · see citing works

The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond

Gilon, D., Iakobishvili, Z., & Leibowitz, D. W. (2022) · Vaccines · doi:10.3390/vaccines10020304 · Cited by 19 · see citing works

Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients

Özdemir, B. C., da Silva, C. E., Arangalage, D., Monney, P. A., Guler, S. A., Huynh‐Do, U., Stirnimann, G., Possamai, L. A., Trepp, R., Hoepner, R., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03436-0 · Cited by 18 · see citing works

Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes

Matsukane, R., Suetsugu, K., Hata, K., Matsuda, K., Nakao, S., Minami, H., Watanabe, H. A., Hirota, T., Egashira, N., & Ieiri, I. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02349-3 · Cited by 17 · see citing works

Immunogenomic correlates of immune-related adverse events for anti–programmed cell death 1 therapy

Zhang, L., Shi, Y., & Han, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032221 · Cited by 16 · see citing works

Investigation of drugs for the prevention of doxorubicin-induced cardiac events using big data analysis

Nishiuchi, S., Yagi, K., Saito, H., Zamami, Y., Niimura, T., Miyata, K., Sakamoto, Y., Fukunaga, K., Ishida, S., Hamano, H., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175083 · Cited by 15 · see citing works

Atrial Fibrillation and Cancer: Pathophysiological Mechanism and Clinical Implications

Mauriello, A., Correra, A., Quagliariello, V., Iovine, M., Micco, P. D., Imbalzano, E., Giallauria, F., Giordano, A., Russo, V., D’Andrea, A., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155600 · Cited by 14 · see citing works

Gender Differences in Diagnosis, Prevention, and Treatment of Cardiotoxicity in Cardio-Oncology

Simek, S. C., Lue, B. K.-H., Rao, A., Ravipati, G., Vallabhaneni, S., Zhang, K., Zaha, V. G., & Chandra, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175167 · Cited by 14 · see citing works

Safety of solid oncology drugs in older patients: a narrative review

Rousseau, A., Géraud, A., Geiss, R., Farcet, A., Spano, J., Hamy, A., & Gougis, P. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103965 · Cited by 14 · see citing works

Association between myocarditis and other immune‐related adverse events secondary to immune checkpoint inhibitor use

Guha, A., Al-Kindi, S. G., Jain, P., Tashtish, N., ElAmm, C. A., & Oliveira, G. H. (2020) · International Journal of Cancer · doi:10.1002/ijc.32960 · Cited by 14 · see citing works

Women at heart: Introducing gender cardio-oncology

Canale, M. L., Bisceglia, I., Gallucci, G., Russo, G., Camerini, A., Fusco, S. A. D., Paccone, A., Camilli, M., Fiscella, D., Lestuzzi, C., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.974123 · Cited by 14 · see citing works

Long-Term Cardiovascular Outcomes of Immune Checkpoint Inhibitor-Related Myocarditis: A Large Single-Centre Analysis

Braghieri, L., Gharaibeh, A., Nkashama, L. J., Abushouk, A. I., Abu-Shawer, O., Mehdizadeh‐Shrifi, A., Honnekeri, B., Calabrese, C. M., Menon, V., Funchain, P., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15131 · Cited by 13 · see citing works

Adverse events associated with potential drugs for COVID-19: a case study from real-world data

Jing, Y., Diao, L., & Han, L. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa234 · Cited by 13 · see citing works

Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis

Fankhauser, R. G., Johnson, D. B., Moslehi, J. J., & Balko, J. M. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00640-2 · Cited by 12 · see citing works

Association between immune checkpoint inhibitor‐induced myocarditis and concomitant use of thiazide diuretics

Mitsuboshi, S., Hamano, H., Niimura, T., Ozaki, A. F., Patel, P. M., Lin, T., Tanaka, Y., Kimura, I., Iwata, N., Shiromizu, S., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34616 · Cited by 12 · see citing works

Arterial Thrombosis in Patients with Cancer

Xu, Y., Carrier, M., & Kimpton, M. (2024) · Cancers · doi:10.3390/cancers16122238 · Cited by 12 · see citing works

Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database

Inoue, M., Matsumoto, K., Tanaka, M., Yoshida, Y., Satake, R., Goto, F., Shimada, K., Mukai, R., Hasegawa, S., Suzuki, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90848-6 · Cited by 12 · see citing works

Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape

Zhu, H., Ivanovic, M., Nguyen, A., Nguyen, P. K. P., & Wu, S. M. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.07.006 · Cited by 11 · see citing works

Molecular mechanisms and therapies of immune checkpoint inhibitor associated myocarditis: Update on recent developments

Li, J., Chen, L., Liu, X., Zhang, M., & Liu, X. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.09.006 · Cited by 11 · see citing works

Prognosis of immune checkpoint inhibitor-related myocarditis: Retrospective experience of a single institution

Qin, Y., Zhang, T., Du, Z., Chen, S., Li, Y., Lv, Y., Du, X., Hu, Y., & Liu, Z. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112385 · Cited by 11 · see citing works

Insight of immune checkpoint inhibitor related myocarditis

Pi, J.-K., Chen, X.-T., Zhang, Y., Chen, X.-M., Wang, Y.-C., Xu, J., Zhou, J.-H., Yu, S.-S., & Wu, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113559 · Cited by 10 · see citing works

Immune Checkpoint Inhibitors Related to Cardiotoxicity

Chen, R., Zhou, M., & Zhu, F. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9110378 · Cited by 10 · see citing works

Italian Association of Hospital Cardiologists Position Paper ‘Gender discrepancy: time to implement gender-based clinical management’

Lucà, F., Pavan, D., Gulizia, M. M., Manes, M. T., Abrignani, M. G., Benedetto, F. A., Bisceglia, I., Brigido, S., Caldarola, P., Calvanese, R., et al. (2024) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae034 · Cited by 10 · see citing works

Risk factors of immune checkpoint inhibitor-related cardiotoxicity: a scoping review

Wang, Y., Zhang, L., Su, Z., & Lian, X. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf187 · Cited by 8 · see citing works

T cells in acute and chronic myocarditis: from diagnosis to treatment

Song, E. J., Joachimbauer, A., Tasca, S., Baylis, R. A., Schmidt, D., Ludewig, B., & Moslehi, J. J. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehaf1080 · Cited by 8 · see citing works

Evaluation of Cardiac Adverse Events with Nivolumab Using a Japanese Real-World Database

Kanbayashi, Y., Shimizu, T., Anzai, M., Kawai, R., & Uchida, M. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01246-x · Cited by 8 · see citing works

Tailored to a Woman’s Heart: Gender Cardio-Oncology Across the Lifespan

Chen, M. H., & Epstein, S. F. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01967-7 · Cited by 8 · see citing works

Recurrent Adrenergic Stress Provokes Persistent Myocarditis in PD-1–Deficient Mice

Hayashi, T., Lim, K. R. Q., Kovacs, A., & Mann, D. L. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2023.07.012 · Cited by 8 · see citing works

Immune checkpoint inhibitor-associated myocarditis: a review of current state of knowledge

Ostos-Mendoza, K. C., Saraiba-Rabanales, V., Gutierrez‐Gallegos, P., Wang, E., Koutroumpakis, E., Kumar, S., Khalaf, S. Z., Ali, H.-J., Deswal, A. M., & Palaskas, N. L. (2025) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.13 · Cited by 7 · see citing works

Multimodal Imaging of Immune Checkpoint Inhibitor Myocarditis

Patel, S. K., DAVE, K. P., Garcia, M. J., Gongora, C. A., Travin, M. I., & Zhang, L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082850 · Cited by 7 · see citing works

Immunotherapy-Associated Cardiotoxicity: Current Insights and Future Directions for Precision Cardio-Oncology

Stefanou, E., Tsitsinakis, G., Karageorgou, D., & Kole, C. (2025) · Cancers · doi:10.3390/cancers17172838 · Cited by 9 · see citing works

Risk Factors for Immune Checkpoint Inhibitor–Related Myocarditis: An Integrative Review

Otto, S., Martinez, A. L., & Dains, J. E. (2024) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2024.15.2.4 · Cited by 11 · see citing works

Case Report: Acute Myocarditis Due to PD-L1 Inhibitor Durvalumab Monotherapy in a Patient With Lung Squamous Cell Carcinoma

Zhou, B., Li, M., Chen, T., & She, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.866068 · Cited by 7 · see citing works

A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma

Chen, Y., Jaffer, M., Zhou, L., Moslehi, J. J., Forsyth, P. A., & Fecher, L. A. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390594 · Cited by 7 · see citing works

Toxicity profile of camrelizumab-based immunotherapy in older adults with advanced cancer

Zhou, H., Cai, L., Lin, Y., & Ma, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-69944-w · Cited by 6 · see citing works

Unmasking the Rare but Lethal Cardiac Complications of Immune Checkpoint Inhibitor Therapy: A Review of Mechanisms, Risk Factors, and Management Strategies

Chehade, L., Abbas, N., Dagher, K., Mourad, M., Amhez, G., Moumneh, M. B., Kreidieh, L., Kreidieh, F., Pereira, M. M. A. M., & Shamseddine, A. I. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01329-1 · Cited by 5 · see citing works

Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database

Ogawa, K., Kozuka, Y., Uno, H., Utsumi, K., Noyori, O., & Hosoki, R. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01042-5 · Cited by 5 · see citing works

Non‐recovery of vancomycin‐associated nephrotoxicity is related to worsening survival outcomes: Combined retrospective analyses of two real‐world databases

Chuma, M., Hamano, H., Bando, T., Kondo, M., Okada, N., Izumi, Y., Ishida, S., Yoshioka, T., Asada, M., Niimura, T., et al. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13799 · Cited by 5 · see citing works

Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity

Zatarain‐Nicolás, E., Martı́n, P., Márquez‐Rodas, I., Virizuela, J. A., Martín‐Garcia, A., Mitroi, C. D., Cosı́n-Sales, J., Barrios, V., Sánchez‐Cabo, F., Ibáñez, B., et al. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03217-2 · Cited by 5 · see citing works

Effect of immune checkpoint inhibitor therapy on biventricular mechanics in cancer patients over a short-term follow-up: a systematic review

Sonaglioni, A., Bruno, A., Nicolosi, G. L., Fossile, E., Rubuano, C., Ricotta, R., Gemelli, M. T., Lombardo, M., Muti, P., & Bassani, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1576175 · Cited by 4 · see citing works

Pharmacovigilance study for the identification of mogamulizumab-induced immune-related adverse events using a real-world database

Miyata, K., Izawa‐Ishizawa, Y., Niimura, T., Yoshioka, T., Hyodo, M., Itokazu, S., Miyata, T., Aizawa, F., Yagi, K., Kawada, K., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf201 · Cited by 4 · see citing works

Angiogenesis inhibitor-specific hypertension increases the risk of developing aortic dissection

Tsujinaka, K., Izawa‐Ishizawa, Y., Miyata, K., Yoshioka, T., Omine, K., Nishi, H., Kondo, M., Itokazu, S., Miyata, T., Niimura, T., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115504 · Cited by 4 · see citing works

THE IMPACT OF ROUTINE CARDIAC TROPONIN I-BASED CARDIOTOXICITY SCREENING ON CLINICAL OUTCOMES IN PATIENTS ON CANCER IMMUNOTHERAPYPreprint

Ivanovic, M., Chan, A., Cheng, E., Xu, S., Lee, C., You, J., Franquiz, M. J., Fazal, M., Batchelder, R., Wu, S. M., et al. (2024) · medRxiv · doi:10.1101/2024.01.22.24301442 · Cited by 4 · see citing works

Immune checkpoint inhibitors and myocarditis–myositis–myasthenia gravis overlap: a FAERS pharmacovigilance study with time-to-onset characterization

Paçacı, B., Yıldırım, B., Tunç, M. A., Demirel, A., Akagündüz, F., Kocaaslan, E., Güren, A. K., Demircan, N. C., & Bayoğlu, İ. V. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1825269 · Cited by 3 · see citing works

Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis

She, J., Liu, H., Wu, H., Tuerhongjiang, G., Zheng, T., & Bai, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.838488 · Cited by 3 · see citing works

Immune checkpoint inhibitors and myocarditis in advanced non-small cell lung cancer: a nationwide cohort study

Li, F.-X., Cai, J., Li, J., Luo, K., Wang, S., Meng, W.-H., Sha, F., Yang, Z., Hackshaw, A. K., & Tang, J.-L. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00325-6 · Cited by 3 · see citing works

Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management

Eftekhar, S. P., Yazdanpanah, N., & Rezaei, N. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1979396 · Cited by 3 · see citing works

Association between Myocarditis and Other Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Use: Analysis of the FDA Adverse Events Reporting System (FAERS)

Tashtish, N., Lang, K., Al-Kindi, S. G., ElAmm, C. A., & Oliveira, G. H. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.07.180

Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems

Ma, R., Wang, Q., Meng, D., Li, K., & Zhang, Y. (2021) · BMC Cancer · doi:10.1186/s12885-020-07741-0 · Cited by 37 · see citing works

Reporting of immune checkpoint inhibitor-associated myocarditis – Authors' reply

Moslehi, J. J., Salem, J., Sosman, J. A., Lebrun‐Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31556-3 · Cited by 10 · see citing works

Association between myocarditis and other immune‐related adverse events secondary to immune checkpoint inhibitor use

Guha, A., Al-Kindi, S. G., Jain, P., Tashtish, N., ElAmm, C. A., & Oliveira, G. H. (2020) · International Journal of Cancer · doi:10.1002/ijc.32960 · Cited by 14 · see citing works

Reporting of immune checkpoint inhibitor-associated myocarditis

Al-Kindi, S. G., & Oliveira, G. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31542-3 · Cited by 51 · see citing works